StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Tango Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Tango Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -253.4%. For fiscal 2025 it was -178.4%, against -346.1% the year before. The highest annual figure on record is -157.1% in fiscal 2021.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-178.4%+167.7
FY2024Dec 31, 2024-346.1%−33.5
FY2023Dec 31, 2023-312.6%+134.2
FY2022Dec 31, 2022-446.8%−289.7
FY2021Dec 31, 2021-157.1%+524.7
FY2020Dec 31, 2020-681.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2025Sep 30, 202526.2%+309.4
Q2 FY2025Jun 30, 2025-1287.9%−1139.2
Q1 FY2025Mar 31, 2025-788.8%−135.8
Q4 FY2024Dec 31, 2024-993.7%−349.0
Q3 FY2024Sep 30, 2024-283.3%−44.5
Q2 FY2024Jun 30, 2024-148.7%+10.6
Q1 FY2024Mar 31, 2024-653.0%−127.7
Q4 FY2023Dec 31, 2023-644.7%−167.9
Q3 FY2023Sep 30, 2023-238.8%+193.6
Q2 FY2023Jun 30, 2023-159.2%+277.5
Q1 FY2023Mar 31, 2023-525.3%−84.5
Q4 FY2022Dec 31, 2022-476.8%−92.2
Q3 FY2022Sep 30, 2022-432.4%−144.1
Q2 FY2022Jun 30, 2022-436.7%−411.6
Q1 FY2022Mar 31, 2022-440.8%−251.6
Q4 FY2021Dec 31, 2021-384.6%−286.8
Q3 FY2021Sep 30, 2021-288.3%–
Q2 FY2021Jun 30, 2021-25.1%–
Q1 FY2021Mar 31, 2021-189.2%–
Q4 FY2020Dec 31, 2020-97.8%–

More Tango Therapeutics figures

See a number that looks wrong?